Specifically, co-administration of IL-2 has been reported to enhance the anti-tumor immune responses of therapies targeting OX40 (CD134), GITR (CD357) and 4-1BB (CD137) [5],[6],[61],[62]. The gene discussed is TNFRSF18; the disease is neoplasm.